Arcturus Therapeutics (NASDAQ:ARCT) Lowered to Sell at StockNews.com

StockNews.com lowered shares of Arcturus Therapeutics (NASDAQ:ARCTGet Rating) from a hold rating to a sell rating in a research note issued to investors on Tuesday morning.

Several other research analysts have also issued reports on ARCT. Wells Fargo & Company initiated coverage on Arcturus Therapeutics in a research report on Monday. They set an overweight rating and a $35.00 target price for the company. Brookline Capital Management reiterated a buy rating on shares of Arcturus Therapeutics in a report on Wednesday, August 10th. Robert W. Baird lowered Arcturus Therapeutics from a neutral rating to an underperform rating and set a $18.00 price target for the company. in a report on Thursday, November 10th. Cantor Fitzgerald boosted their price target on Arcturus Therapeutics from $39.00 to $44.00 and gave the company an overweight rating in a report on Wednesday, November 2nd. Finally, The Goldman Sachs Group boosted their price target on Arcturus Therapeutics from $8.00 to $14.00 and gave the company a sell rating in a report on Thursday, November 10th. Four research analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, Arcturus Therapeutics presently has an average rating of Hold and an average target price of $28.25.

Arcturus Therapeutics Stock Down 1.3 %

Shares of NASDAQ:ARCT opened at $18.00 on Tuesday. Arcturus Therapeutics has a 1 year low of $11.70 and a 1 year high of $48.75. The business has a 50 day simple moving average of $16.51 and a two-hundred day simple moving average of $16.98. The firm has a market capitalization of $476.87 million, a PE ratio of -3.24 and a beta of 2.51. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.25 and a quick ratio of 3.25.

Institutional Trading of Arcturus Therapeutics

A number of hedge funds have recently bought and sold shares of ARCT. Great West Life Assurance Co. Can purchased a new stake in Arcturus Therapeutics during the third quarter worth $27,000. Amalgamated Bank acquired a new position in shares of Arcturus Therapeutics during the first quarter worth $69,000. BNP Paribas Arbitrage SA increased its position in shares of Arcturus Therapeutics by 63.4% during the second quarter. BNP Paribas Arbitrage SA now owns 5,043 shares of the biotechnology company’s stock worth $79,000 after purchasing an additional 1,956 shares in the last quarter. Daiwa Securities Group Inc. increased its position in shares of Arcturus Therapeutics by 44.0% during the first quarter. Daiwa Securities Group Inc. now owns 3,503 shares of the biotechnology company’s stock worth $94,000 after purchasing an additional 1,071 shares in the last quarter. Finally, Point72 Hong Kong Ltd increased its position in shares of Arcturus Therapeutics by 3,653.2% during the second quarter. Point72 Hong Kong Ltd now owns 6,493 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 6,320 shares in the last quarter. Hedge funds and other institutional investors own 83.55% of the company’s stock.

Arcturus Therapeutics Company Profile

(Get Rating)

Arcturus Therapeutics Holdings Inc, an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU.

Featured Stories

Analyst Recommendations for Arcturus Therapeutics (NASDAQ:ARCT)

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.